NEW YORK (360Dx) – Researchers at Cleveland HeartLab have developed a pair of proteomic tests for measuring cholesterol efflux capacity (CEC) and assessing patient risk of coronary artery disease (CAD).
NEW YORK (360Dx) – Researchers at Cleveland HeartLab have developed a pair of proteomic tests for measuring cholesterol efflux capacity (CEC) and assessing patient risk of coronary artery disease (CAD).
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.